RTTNews | Nov 22, 2021 07:50AM EST

07:49 Monday, November 22, 2021 (RTTNews.com) - Mirati Therapeutics Inc. (MRTX) and Verastem Oncology (VSTM) have collaborated to evaluate the combination of Mirati's investigational KRASG12C inhibitor adagrasib with Verastem Oncology's investigational RAF/MEK inhibitor VS-6766 in KRASG12C-mutant non-small cell lung cancer (NSCLC), the companies said in a statement.

The primary objective of Phase 1/2 trial is to determine the maximum tolerated dose and recommended Phase 2 dose for the combination of adagrasib and VS-6766 in patients with KRASG12C-mutant NSCLC.

The study will also investigate the safety, tolerability and efficacy of the combination in patients who have progressed on a KRASG12C inhibitor. The trial will build on preclinical data showing deeper blockade of ERK pathway signaling resulting in enhanced anti-tumor efficacy with the combination of adagrasib and VS-6766 relative to either agent alone.

Read the original article on RTTNews ( https://www.rttnews.com/3244038/mirati-verastem-to-evaluate-adagrasib-vs-6766-in-krasg12c-mutant-non-small-cell-lung-cancer.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved